Roche Pharmaceutical Development and Sales Overview

Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy - SCCHN and melanoma Indication Adjuvant squamous cell carcinoma of the head and neck (SCCHN) Phase/study # of patients ARM A: Tecentriq 1200mg q3w Design Primary endpoint Status CT Identifier ☐ ARM B: Placebo Event-free survival and overall survival ◉ FPI Q1 2018 Recruitment completed Q1 2020 SCCHN-squamous cell carcinoma of the head and neck Phase III IMvoke010 N=406 NCT03452137 Roche 69 。 Oncology

View entire presentation